ClinicalTrials.gg
RecruitingNCT07204340Updated Jul 28, 2026

TLN-372 in Advanced KRAS Mutant Solid Tumors

A Phase 1 interventional study of TLN-372 and TLN-372 in combination with cetuximab in KRAS Mutant Solid Tumors, sponsored by Treeline Biosciences, Inc.. Recruiting at 11 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-28.

Sponsored by Treeline Biosciences, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
270
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary purpose of this study is to evaluate the safety, pharmacokinetics, and anti-tumor activity of TLN-372 as a single agent and in combination with other anti-tumor agents, in patients with advanced KRAS mutant solid tumors

02

Conditions studied

  • KRAS Mutant Solid Tumors

Keywords

  • KRAS mutant solid tumors
  • KRAS
03

In context

Lead sponsor

Treeline Biosciences, Inc. is the lead sponsor of 4 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients must have at study entry.
  2. Patients must have locally advanced or KRAS mutant solid tumors.
  3. (ECOG) performance status of 0 or 1.
  4. Adequate organ function.

Exclusion criteria

Exclusion Criteria:

  1. Patients must not have active .
  2. Patients must not have current or past history of central nervous system (CNS) involvement.
  3. Patients must not have major surgery or severe trauma within 4 weeks prior to the start of the study.
  4. Patients must not have any condition, including significant acute or chronic medical illness, active or uncontrolled infection, or the presence of laboratory abnormalities, that places patients at unacceptable risk of participating in this study.
  5. Patients must not have cardiovascular disease.
  6. Pregnant or lactating.
  7. Conditions that could affect drug absorption.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
270 participants (estimated)

Study arms

  • Experimental
    Single Agent

    Drug: TLN-372

  • Experimental
    Combination Treatment

    Drug: TLN-372 in combination with cetuximab · Drug: TLN-372 in combination with pembrolizumab

Interventions

  • DrugTLN-372

    Specified dose on specified days

  • DrugTLN-372 in combination with cetuximab

    Drug page: Cetuximab

    Specified dose on specified days

  • DrugTLN-372 in combination with pembrolizumab

    Drug page: Pembrolizumab

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Number of patients experiencing adverse events (AEs) that meet protocol-defined dose-limiting toxicity (DLT) criteria following administration of TLN-372

    Time frame: Up to 2 years

  2. Incidence and severity of Treatment-Emergent Adverse Events (TEAEs) and Treatment-Related Adverse Events (TRAEs) leading to dose modification and discontinuation.

    Time frame: Up to 2 years

  3. Anti-tumor activity of TLN-372 by evaluating the objective response rate (ORR) according to the RESIST v1.1

    Time frame: Up to 2 years

Secondary outcomes

  1. Maximum observed plasma concentration (Cmax) of TLN-372

    Time frame: Up to 2 years

  2. Time to peak drug concentration (Tmax) of TLN-372

    Time frame: Up to 2 years

  3. Minimum observed plasma concentration (Cmin) of TLN-372

    Time frame: Up to 2 years

  4. Area Under the Plasma Concentration-Time Curve (AUC) of TLN-372

    Time frame: Up to 2 years

  5. Anti-tumor activity of TLN-372 by evaluating the duration of response (DOR) as assessed by the time from the date of first objective response to the date of disease progression

    Time frame: Up to 2 years

  6. Frequency of dose interruptions, reductions and dose intensity

    Time frame: Up to 2 years

  7. Clinically significant ECG QT Interval from baseline in safety laboratory test results, assessed as per NCI CTCAE v5.0

    Time frame: Up to 2 years

  8. Clinically significant laboratory abnormalities from baseline in safety laboratory test results, assessed as per NCI CTCAE v5.0

    Time frame: Up to 2 years

07

Study locations

11 of 11 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Dec 2031, 74 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2025
First posted
Oct 2, 2025
StartActual
Sep 29, 2025
Primary completionEst.
Dec 3, 2031
CompletionEst.
Apr 1, 2032
Last update
Jul 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07204340
Lead sponsor
Treeline Biosciences, Inc.
Responsible party
Sponsor
First posted
Oct 2, 2025
Start date
Sep 29, 2025
Primary completion
Dec 3, 2031 (estimated)
Completion
Apr 1, 2032 (estimated)
Last update
Jul 28, 2026

Study contacts

Treeline Clinical Operations
Contact
clinicaloperations@treeline.bio
857-228-0050

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cetuximab · Pembrolizumab

Start the discussion